HomeCompareCALT vs VICI

CALT vs VICI: Dividend Comparison 2026

CALT yields 5.00% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $961.0K in total portfolio value
10 years
CALT
CALT
● Live price
5.00%
Share price
$40.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$688.45
Full CALT calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — CALT vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCALTVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CALT + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CALT pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CALT
Annual income on $10K today (after 15% tax)
$425.00/yr
After 10yr DRIP, annual income (after tax)
$585.18/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $529,186.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CALT + VICI for your $10,000?

CALT: 50%VICI: 50%
100% VICI50/50100% CALT
Portfolio after 10yr
$508.3K
Annual income
$311,974.89/yr
Blended yield
61.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CALT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$39.50
-1.3% upside vs current
Range: $39.00 — $40.00
Altman Z
8.0
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CALT buys
0
VICI buys
0
No recent congressional trades found for CALT or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCALTVICI
Forward yield5.00%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$27.8K$988.8K
Annual income after 10y$688.45$623,261.32
Total dividends collected$6.0K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$39.50$31.60

Year-by-year: CALT vs VICI ($10,000, DRIP)

YearCALT PortfolioCALT Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$11,200$500.00$11,368$948.43$168.00VICI
2$12,507$523.36$13,339$1,493.16$832.00VICI
3$13,929$546.22$16,326$2,426.21$2.4KVICI
4$15,473$568.51$21,123$4,112.15$5.7KVICI
5$17,146$590.20$29,379$7,368.23$12.2KVICI
6$18,957$611.24$44,804$14,191.64$25.8KVICI
7$20,916$631.60$76,658$29,972.12$55.7KVICI
8$23,031$651.27$150,894$71,015.81$127.9KVICI
9$25,314$670.22$350,814$193,582.47$325.5KVICI
10$27,774$688.45$988,809$623,261.32$961.0KVICI

CALT vs VICI: Complete Analysis 2026

CALTStock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Full CALT Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CALT vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CALT vs SCHDCALT vs JEPICALT vs OCALT vs KOCALT vs MAINCALT vs NNNCALT vs EPRTCALT vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.